Post X-Waiver Substance Use Disorder Training Module 7: Opioid Use Disorder 201
Available through Jun 21, 2025 Open Medicine
![Post X-Waiver Substance Use Disorder Training Module 7: Opioid Use Disorder 201](/images/events/_medium/event-71332v2.jpg)
Description
Register now for this online, self-guided course!
This module will first provide a background on the opioid epidemic and its effects on North Carolina. It will then identify the different pharmacological treatments for opioid use disorder (MOUD) and describe the differences in these medications including their efficacy, pharmacology, and historical and political regulation. It then will describe how buprenorphine is prescribed and how opioid withdrawal is managed.
Approximate time to complete the course: 1 hour
Learner content includes: video and corresponding course handouts
Participants have unlimited time to complete this course and access course materials
This training module is part of a training suite that has been developed in accordance with the recommendations from the DEA and SAMHSA for the Medication Access and Training Expansion (MATE) Act. This requirement applies to physicians, physician assistants, nurse practitioners, podiatrists, dentists, and other practitioners that prescribe controlled substances who are applying for or renewing their DEA license after June 27, 2023.
Click here for more information and a full listing of modules available.
MAHEC engages in evaluation activities to better understand the impact of our programs. By registering for this course, you agree that we may use your personal information in evaluative research regarding this program. Any reports published will be de-identified and reported in aggregate format.
With Support From
![GI](http://sys.mahec.net/media/arialimages/GI-logo.png)
Target Audience
This program is recommended for physicians, physician assistants, nurse practitioners, podiatrists, dentists, and other practitioners that prescribe controlled substances.
Objectives
- Apply your understanding of the pharmacology of the three FDA approved medications for the treatment of opioid use disorder in using them most effectively
- Demonstrate an understanding of who can prescribe which three FDA approved medications for opioid use disorder
- Analyze the safety of the buprenorphine-naloxone combination product
Faculty
- Carriedelle H. Fusco, RN, MSN, FNP-BC
Sessions
Post X-Waiver Substance Use Disorder Training Module 7: Opioid Use Disorder 201
6/21 1:00 AM – 1:00 AM
Credits
.100 CEU
The Mountain Area Health Education Center designates this entire online continuing education activity as meeting the criteria for 0.1 CEUs as established by the National Task Force on the Continuing Education Unit.
1.000 Contact Hours
Nurse Practitioners: This activity was designated for 1.00 AMA PRA Category 1 Credit™.
And
All Other Providers, including Dental Providers: MAHEC designates this online continuing education activity as meeting the criteria for 1.00 Contact Hour.
1.000 CME for Physician Assistants
Physician Assistants: AAPA accepts certificate of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.
1.000 AMA PRA Category 1 Credit TM
Accreditation: The Mountain Area Health Education Center (MAHEC) is accredited by the Southern States CME Collaborative to provide continuing medical education for physicians.
Credit Designation: MAHEC designates this online enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.